More severe psoriasis explains the higher costs of care for men

May 15, 2013

Men often suffer from more severe cases of psoriasis than women, which may explain why the cost of care for men is higher. This is the conclusion of researchers at Sweden's Umeå University in a new study.

It is known that psoriasis affects about as many women as men. However, it has been shown, both in Sweden and internationally, that men receive more frequent and more expensive care for their disease, compared to women.

"We find these differences unsettling, which is why we performed this study," says the senior author of the study, Marcus Schmitt-Egenolf, chief physician at the Dermatology & STI clinic of Norrland's University Hospital and associate professor at Umeå University. "While the study cannot rule out that women receiving psoriasis care are discriminated against, it does indicate that gender variations in care consumption are mainly caused by a greater severity of illness in men. It is important to incorporate the issue of the differences in the degree of severity into the debate about gender inequality in medical care."

In the study, which has been published in the open access journal PLOS One, data from 2,294 Swedish patients with moderate to severe psoriasis was analysed. The study focused on the degree of severity of the illness in women and men, and at what stage of the symptoms biologics were administered. Biologics are a relatively new treatment and, being more costly than traditional treatment methods, are therefore often used when other treatments prove ineffective.

Data on patients' disease were obtained from the National Psoriasis registry PsoReg, which include, among other things, records of treatment with biologics.

The study shows that men had more severe symptoms than women, according to the Psoriasis Area and Severity Index, PASI, which is an established tool to evaluate the treatment effect on the skin.

The men had a significantly higher PASI score at the first contact with a dermatologist. When treatment with biologics was initiated, the average PASI score was 12.3 in men compared with 9.8 in women. Age, disease severity and joint involvement were factors that played a significant role in the decision to use biologics, while sex itself did not appear to have any significance.

"According to the results of the study", says Marcus Schmitt-Egenolf, "men with psoriasis have more severe symptoms than women, which in turn could explain why they receive more rigorous treatment at an earlier stage of the disease."

Marcus Schmitt-Egenolf, who is also responsible for the quality registry PsoReg, is convinced that the Swedish quality registries are an important instrument for achieving equality in care.

"One of the reasons why we set up PsoReg was to ensure that women and men get the same access to modern medicines," says Marcus Schmitt-Egenolf.
-end-


Umea University

Related Psoriasis Articles from Brightsurf:

Most psoriasis patients taking immunosuppressants survive COVID-19
Patients with psoriasis who are taking drugs that affect their immune system have high rates of survival from COVID-19.

Getting under the skin of psoriasis
Psoriasis afflicts millions of people worldwide, but treatments are limited to small molecules like steroids, which can cause skin thinning and lose their effectiveness over time.

Psoriasis patients' mental health is more than skin-deep
A new study from Umeå University, Sweden, shows that other somatic diseases have even more impact on patients' mental health than their skin symptoms, highlighting the importance of holistic patient care.

Psoriasis: Towards a novel therapeutic approach
Researchers at the Université libre de Bruxelles (ULB) and the Department of Dermatology of the Erasme hospital uncover the importance of VEGFA signaling in the epidermis to mediate psoriasis development.

Insights into psoriasis suggest a new treatment target
Investigators from Brigham and Women's Hospital and the Harvard Stem Cell Institute have uncovered a novel pathway that may explain why skin thickens in psoriasis and suggests new strategies for developing therapies for the condition.

Psoriasis onset determines if psoriatic arthritis patients develop arthritis or psoriasis first
In a new study presented at the 2019 ACR/ARP Annual Meeting, researchers found the age of psoriasis onset determines whether arthritis or psoriasis starts first in people with psoriatic arthritis.

Study: Some biologic treatments for psoriasis may be safer for patients
In the largest study of its kind, Erica D. Dommasch, M.D., M.P.H., a dermatologist in the Department of Dermatology at BIDMC, and colleagues found a decreased risk of infection in patients with psoriasis using some of the newer, more targeted medications compared to those taking methotrexate, a drug widely used since the 1960s as a first line treatment for moderate-to-severe psoriasis.

Higher weight increases risk of psoriasis
The higher a person's BMI, the greater the chance of getting psoriasis.

Lipid that aids normal skin turnover may help psoriasis
Topical application of the lipid phosphatidylglycerol, or PG, on a mouse model of psoriasis reduced inflammation as well as characteristic, raised skin lesions, they report in the Journal of Investigative Dermatology.

New insight into the mechanism of the drug against sclerosis and psoriasis
A multidisciplinary research team at Aarhus University has provided fundamental new insight into the mechanism of the medical drug dimethyl fumarate, which is the active component of important treatments for multiple sclerosis and psoriasis.

Read More: Psoriasis News and Psoriasis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.
Can't connect to localhost. Errorcode: 1203